Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Chemokines and eicosanoids fuel the hyperinflammation within the lungs of patients with severe COVID-19

Younes Zaid, PhD,a,b Etienne Doré, MSc,c,d Isabelle Dubuc, DEC,e Anne-Sophie Archambault, MSc,e,f Olivier Flamand, BSc,f Michel Laviolette, MD,g Nicolas Flamand, PhD,e,f Eric Boilard, PhD,e,d,g and Louis Flamand, PhD, MBA,c,g

Rabat, Morocco; and Québec City, Québec, Canada

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can lead to a variety of clinical outcomes, ranging from the absence of symptoms to severe acute respiratory disease and ultimately death. A feature of patients with severe coronavirus disease 2019 (COVID-19) is the abundance of inflammatory cytokines in the blood. Elevated levels of cytokines are predictive of infection severity and clinical outcome. In contrast, studies aimed at defining the driving forces behind the inflammation in lungs of subjects with severe COVID-19 remain scarce.

Objective: Our aim was to analyze and compare the plasma and bronchoalveolar lavage (BAL) fluids of patients with severe COVID-19 (n = 45) for the presence of cytokines and lipid mediators of inflammation (LMIs).

Methods: Cytokines were measured by using Luminex multiplex assay, and LMIs were measured by using liquid chromatography–tandem mass spectrometry.

Results: We revealed high concentrations of numerous cytokines, chemokines, and LMIs in the BAL fluid of patients with severe COVID-19. Of the 13 most abundant mediators in

Disclosure of potential conflicts of interest: The authors declare that they have no relevant conflicts of interest.

Received for publication March 5, 2021; revised May 10, 2021; accepted for publication May 19, 2021.

Available online June 7, 2021.

Corresponding author: Louis Flamand, PhD, MBA, Centre de Recherche du CHU-CHUL, 2705 Laurier Boulevard, Office T1-49, Québec City, QC G1V 4G2, Canada. E-mail: louis.flamand@crchudequebec.ulaval.ca.

The CrossMark symbol notifies online readers when updates have been made to the article such as errata or minor corrections 0091-6749 © 2021 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

https://doi.org/10.1016/j.jaci.2021.05.032
Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease spectrum associated with SARS-CoV-2 infection varies extensively from asymptomatic to severely ill, with an estimated overall death rate of 2%. For the most part, children showed limited symptoms of infection whereas elderly individuals (>75 years) and those with risk factors, including severe obesity, lung and heart diseases, diabetes, and immunosuppression, develop the severe clinical form of the disease. The mortality rate increases dramatically to 40% to 50% in elderly individuals and subjects with a severe form of the disease. SARS-CoV-2 is transmitted via aerosols, and the alveolar type II epithelial cells expressing the angiotensin-converting enzyme 2 receptor are one of their primary cell targets. The injury to type II epithelial cells resulting from the inflammatory immune response initiated by SARS-CoV-2 infection induces accumulation of fluids, with the alveolar space impairing gas exchange, which in turn results in an acute respiratory disease syndrome (ARDS) requiring mechanical breathing assistance and supplemental oxygen.

Soon after the initial characterization of SARS-CoV-2, it became clear that subjects with severe forms of the disease showed enhanced levels of circulating inflammatory cytokines. Ever since, the expression cytokine storm has been used to describe the overwhelming and dysregulated immune response triggered by the virus. The majority of studies have used blood, plasma, and/or serum as biologic matrices to monitor the inflammatory response during COVID-19. In such studies, increased circulating levels of IL-6, TNF-α, IL-2R, IL-8, monocyte chemotactant protein-1, and macrophage inflammatory protein-1α were measured relative to the levels in healthy subjects or those with mild COVID-19. Although statistically significant cytokine levels were measured, in most cases the cytokine concentrations in patients with severe COVID-19, such as IL-6, are 10- to 200-fold lower than the IL-6 levels typically observed in patients with ARDS-related inflammation. One question arising from these observations is whether blood, plasma, or serum represent reliable biologic matrices to evaluate the extent and nature of lung inflammation in patients with severe COVID-19. This question is of critical importance, as the optimal therapeutics may be designed on the basis of the identified circulating molecules.
TABLE I. Clinical characteristics of BAL fluid donors

| Characteristic                        | Severe COVID-19 (n = 45) | Healthy controls (n = 25) |
|--------------------------------------|---------------------------|---------------------------|
| Women/men, no./no.                  | 19/26                     | 16/9                      |
| Death (Y/N), no./no.                | 2/43                      | N/A                       |
| Level of SARS-CoV-2 detection in BAL fluid (no.), mean ± SD | 25.62 ± 4.99 | N/A |
| Age (y), mean ± SD                  | 57.67 ± 18.15             | 26.13 ± 1.03              |
| Weight (kg), mean ± SD              | 75.12 ± 15.87             | N/A                       |
| Hospital stay (d), mean ± SD        | 19.00 ± 11.32             | N/A                       |
| Time hospitalized before BAL (d), mean ± SD | 3.24 ± 3.79 | N/A |
| Blood eosinophil level (10^6/mL), mean ± SD | 73.33 ± 15.81 | N/A |
| Blood neutrophil level (10^6/mL), mean ± SD | 32.18 ± 0.000 | N/A |
| Platelet-to-lymphocyte ratio, mean ± SD | <150                     | N/A                       |
| d-Dimer level (mg/mL), mean ± SD    | 1.16 ± 0.72               | N/A                       |
| CRP level (mg/L), mean ± SD         | 21.17 ± 13.86             | N/A                       |
| ALT level (U/L), mean ± SD          | 33.80 ± 13.29             | N/A                       |
| AST level (U/L), mean ± SD          | 35.81 ± 16.18             | N/A                       |
| LDH level (U/L), mean ± SD          | 637.56 ± 229.28           | N/A                       |
| Hemoglobin level (g/L), mean ± SD   | 122.42 ± 14.46            | N/A                       |
| Blood monocyte level (10^3/mL), mean ± SD | 0.34 ± 0.18              | N/A                       |
| Blood neutrophil level (10^3/mL), mean ± SD | 2.81 ± 1.00              | N/A                       |
| Blood eosinophil level (10^3/mL), mean ± SD | 0.02 ± 0.01              | N/A                       |
| Blood platelet level (10^3/mL), mean ± SD | 173.91 ± 73.09            | N/A                       |
| Blood lymphocyte level (10^3/mL), mean ± SD | 1.13 ± 0.73              | N/A                       |
| Platelet-to-lymphocyte ratio, mean ± SD | 215.53 ± 179.95           | N/A                       |
| BAL neutrophil level (10^3/mL), mean ± SD | 22.66 ± 12.01             | N/A                       |
| BAL eosinophil level (10^3/mL), mean ± SD | 0.17 ± 0.38              | 0.000 ± 0.0002            |
| BAL lymphocyte level (10^3/mL), mean ± SD | 22.68 ± 13.48             | 0.004 ± 0.001             |

ALT, Alanine transaminase; CRP, C-reactive protein; F, female; FiO2, fraction of inspired oxygen; LDH, lactate dehydrogenase; M, male; N, no; N/A, not available/applicable; Y, yes.

METHODS

Ethics

This study (project identifier CEFCZ/PR/2020- PR04) was approved by the local ethics committee of Cheikh Zaid Hospital, Rabat, Morocco, and it complies with the principles of the Declaration of Helsinki. All subjects signed a consent form. The analyses of cytokines in the BAL fluid of healthy donors and patients with severe COVID-19 was approved by the Comité d’éthique de la recherche du CHU de Québec-Université Laval.

Clinical criteria for subject selection

Nonsmoking healthy subjects taking no medication (including steroids or antivirals) other than contraceptive pills, without any documented acute or chronic inflammatory disease, and without recent (within the past 8 weeks) airway infection were recruited for collection of BAL fluid. Patients were categorized as having severe COVID-19 on the basis of clinical criteria developed by the American Thoracic Society guidelines for community-acquired pneumonia. Patients with severe COVID-19 were consecutively enrolled on the basis of inclusion criteria for intubation and the need for mechanical ventilation support. Following intubation and initiation of mechanical ventilation, blood sampling was performed to assess the clinical variables shown in Table II. Additional clinical characteristics of the volunteers are also summarized in Table I. Comorbidities and medication taken by the subjects with severe COVID-19 are provided in Tables E1 and E2 (available in this article’s from the Online Repository at www.jacionline.org).

Clinical data and blood work

All laboratory blood work was performed in the COVID-19 laboratory dedicated solely to the pandemic at Cheikh Zaid Hospital. Patients’ demographic data, clinical reports, 2 sets of laboratory blood work results, and treatment protocols were collected, analyzed, and compared for clinical outcomes.

BAL

BAL fluids from healthy volunteers (n = 25) were obtained as follows: A single 50-mL bolus of sterile 0.9% saline was injected into a subsegmental bronchus of the right middle lobe. The recovered fluid was centrifuged (at 350 g for 10 minutes) to pellet cells, and the supernatants were immediately frozen (–80°C) until further processing. A 5-mL aliquot of the samples was thawed and then reduced to approximately 500 μL by using a stream of nitrogen. BAL fluid from patients with severe COVID-19 (n = 45) was obtained less than 2 hours following intubation. It was obtained as follows: a total of 100 mL of sterile 0.9% saline in 2 boli of 50 mL each was injected into a subsegmental bronchus of the right middle lobe. The obtained lavage fluids were pooled and centrifuged (at 320 g for 15 minutes) to pellet cells. The supernatants were next concentrated as for the BAL fluid of healthy donors by using a stream of nitrogen and immediately frozen (–80°C) until further processing. All of the evaporated samples were processed for liquid chromatography–tandem mass spectrometry (LC-MS/MS) analysis as described in the following sections.

Plasma samples

Venous blood was drawn from healthy subjects (n = 10 [subjects different from those who provided BAL fluid samples]) and patients with COVID-19 (n = 45 [the same patients used for providing BAL]) in accordance with guidelines of the Ethics Committee of Cheikh Zaid Hospital of Rabat. Blood samples were anticoagulated in one-sixth volume of acid citrate dextrose (2.5 g of sodium citrate, 2 g of glucose, and 1.5 g of citric acid in 100 mL of deionized water). Platelet-rich plasma was obtained by centrifugation of anticoagulated blood at 200 g for 15 minutes. Platelets were then removed from plasma by centrifugation (1000 g for 10 minutes). Platelet-free plasma were aliquoted and stored frozen until being assayed for cytokine content.

Cytokine assay

Cytokine levels in plasma were assessed by Eve Technologies Corp (Calgary, Alberta, Canada) by using the Human Cytokine Array/Chemokine
Array 71-Plex (HD71). BAL fluid samples were diluted 1:5 with saline before analysis. Cytokine levels are reported as pg/mL of plasma and pg/mL of BAL fluid from individuals who had recuperated.

LC-MS/MS analyses
Samples (500 µL) were denatured by adding 500 µL of LC-MS/MS-grade MeOH (Fisher Scientific, Ottawa, Ontario, Canada) containing the internal standards (Cayman Chemical, Ann Arbor, Mich) and then warmed at 60°C for 30 minutes to inactivate (or not) SARS-CoV-2. Samples were then denatured overnight (at −20°C). Samples were analyzed on a Shimadzu 8050 triple quadrupole mass spectrometer as previously described.25

Statistical analyses
Statistical analyses were done by using GraphPad Prism 9 software (GraphPad Software Inc, San Diego, Calif). Data were tested for normal distribution by the Shapiro-Wilk test. Data that fit the assumption of normal distribution were compared by using parametric analysis, as indicated in the respective figure legends. Student unpaired or paired t tests were used for comparing data from 2 groups. Data that did not fit the assumption of normal distribution were compared by using nonparametric analysis indicated in the respective figure legends. A nonparametric correlation matrix was calculated by comparing BAL fluid and plasma analytes as well as biochemical variables in a pairwise fashion by using the corrtest function from the psych CRAN package: the corrplot package was subsequently used to graphically display the correlation matrix. Spearman correlation coefficients were indicated by a heat scale according to which blue indicates a positive linear correlation and red indicates a negative linear correlation. P values less than .05 were considered significant.

RESULTS
Plasma samples from 45 patients with severe COVID-19 were analyzed for their content of 71 cytokines and chemokines. As reported by others,24,5,6 many of the analytes measured were present at significantly higher concentrations in the blood of patients with COVID-19 than in the blood of healthy controls (Fig 1). The levels of cytokines such as IL-1α, IL-β, TNF-β, and IFN-γ were all elevated (Fig 1, A), whereas no significant differences in IL-6 levels were noted. Chemokines of the CC family (notably, CCL2, CCL3, CCL4, CCL5, and CCL11) were present at significantly higher concentrations in the blood of patients with COVID-19 (Fig 1, B). The levels of chemokines of the CXC family (notably, CXCL1 and CXCL8) were also significantly upregulated (Fig 1, C). No difference in the levels of CXCL1 was observed. Examples of positive (IL-1β and CXCL8) and negative (CXCL5 and CCL3) correlations are presented under Fig 1, D and E, respectively. Correlation analyses between plasmatic cytokines indicated a variety of patterns ranging from positive to negative to an absence of correlation (Fig 1, F). CXCL5 level was negatively correlated with multiple cytokines.

The cytokine and chemokine contents in BAL fluids of the same 45 patients with severe COVID-19 were analyzed (Table 1 and Fig 2). High concentrations of several cytokines (Fig 2, A), CC chemokines (Fig 2, B), and CXC chemokines (Fig 2, C) were detected. The most abundant analytes measured were CXCL1, CXCL8, CCL2, and CCL15. For purposes of comparison, BAL fluids from healthy subjects were analyzed for the same analytes. Acknowledging potential biases due to differences in age and medication taken, all of the analytes measured (with the exception of IL-28A) were detected at significantly higher concentrations in BAL fluids of subjects with severe COVID-19 than in the BAL fluids of healthy subjects. Correlations between analytes were subsequently analyzed. An example of positive correlation between CXCL1 and CXCL8 (r = 0.097; P < .0001) is presented in Fig 2, D. The correlation matrix of BAL fluid analytes is presented under Fig 2, E. As shown, very significant positive correlations were observed between most of the BAL fluid cytokines analyzed.

LMs represent another important class of molecules that play very important roles in inflammation and whose contributions to COVID-19 disease remain understudied. LMs of the eicosanoid class originate from the processing of arachidonic acid generated by the cleavage of membrane phospholipids by phospholipase A2 (Fig 2, F). Arachidonic acid can be processed by cyclooxygenases and lipoxygenases to produce prostaglandins, thromboxanes, and leukotrienes. BAL fluids of healthy and subjects with severe COVID-19 were analyzed for the presence of selected eicosanoids. Relative to the concentrations in healthy controls, the concentrations of PG-E2, TXB2, 12-HHTe, and leukotriene B4 (LTB4) detected in the BAL of subjects with COVID-19 were significantly higher. Such LMs showed significant positive correlations with most of the BAL fluid cytokines analyzed (Fig 2, G).

Whether the portrait of inflammatory molecules measured in the blood mirrors that in the lungs in COVID-19 is unknown. We thus determined whether individual analyte levels were correlated between plasma and BAL fluids. Of relevance, plasma and BAL fluid samples were obtained from same donor a few hours apart on the same day. A total of 10 analytes (IL-1α, IL-6, TNF-α, IL-12p70, IL-22, IFN-α2, CCL2, CCL11, CXCL9, and CXCL10) showed positive and significant correlations in BAL fluid and plasma (Fig 3, A and B). CXCL5 showed a negative correlation between plasma and BAL fluid samples. A summary of other significant correlations detected between BAL fluid and plasma analytes is presented in Fig E1 (available in the Online Repository at www.jacionline.org).

We next evaluated whether the blood represents a reliable matrix reflecting the lung pathophysiology observed during severe COVID-19. By plotting the absolute concentrations of analytes measured in plasma and BAL fluids we observed that most analytes were detected at much higher levels in plasma than in BAL fluids (Fig 4, A). Notable exceptions included CXCL1 and CXCL8. Relative to plasma, CXCL1 and CXCL8 concentrations were 30 times higher in the BAL fluids. As cells respond to chemotactic stimuli in a gradient-dependent manner, CXCL1 and CXCL8 in lungs are likely the main driving force behind neutrophil and lymphocytic pulmonary influxes (Fig 4, B and F–G). Other cytokines such as CX3CL1, CCL2, and CCL3 were detected at similar concentrations, whereas yet others such as CCL15 and CXCL5 were much more abundant in plasma relative to BAL fluids. Of all the cytokines, chemokines, and growth factors measured in BAL fluids of patients with severe COVID-19, the most abundant were CXCL8 (mean and median 1115 and 843 pg/mL, respectively) and CXCL1 (mean and median values of 1353 and 666 pg/mL, respectively) (Fig 4, C). In fact, of the 13 most abundant analytes detected in BAL fluids of patients with severe COVID-19, 11 (85%) belong to the chemokine class of mediators, the other 2 being EGF and VEGF-A. With mean averages greater than 1000 pg/mL in BAL fluids, CXCL1 and CXCL8 exceeded the concentration of inflammatory cytokines such as IL-1β, IL-6, and TNF-α by more than 200-fold (Fig 4, C). Male and female individuals with severe COVID-19 produced CXCL1 and CXCL8 to similar levels (Fig 4, D and E). Of potential pathophysiologic importance, the increased
cytokine and chemokine levels in the BAL fluids of patients with severe COVID-19 were accompanied by a robust influx of both neutrophils and lymphocytes (Fig 4, F and G). Although the lymphocytic and neutrophilic contents of BAL fluids of healthy controls were marginal, those of patients with severe COVID-19 contained several million leukocytes per milliliter.
FIG 2. Analysis of cytokines, chemokines, and growth factors in BAL fluid of patients with severe COVID-19 (n = 45) and healthy subjects (n = 25). A, BAL fluid concentrations of various cytokines and interferons. B, BAL fluid concentrations of various CC chemokines. C, BAL fluid concentrations of various CXC chemokines. D, Example of positive correlation between CXCL8 and CXCL1. E, Summary of Spearman correlations between cytokines in BAL fluid of subjects with severe COVID-19. F, Diagram showing generation of arachidonic acid following membrane phospholipid hydrolysis by cPLA2 and subsequent processing into various LMs. G, Summary of Spearman correlations between LMs and cytokines in BAL fluid of subjects with severe COVID-19. In this figure, COVID-19 refers to patients with severe COVID-19. Results are presented as scattered plots with median concentrations shown by horizontal bars. ****P < .0001, as determined using the Mann-Whitney nonparametric test. HS, Healthy subject.
Eosinophils, which were absent from BAL fluids of control subjects, were detected in most of the BAL fluid samples from patients with severe COVID-19 (Fig 4, H).

By far, the most abundant analyte measured in plasma of subjects with severe COVID-19 was PDGF-AB/BB. Relative to the levels in healthy controls, PDGF-AB/BB levels were highly significantly elevated (Fig 5, A). PDGF-AB/BB levels were also significantly elevated in the BAL fluids of patients with severe COVID-19 relative to those in BAL fluids of healthy subjects (Fig 5, B). PDGF-AB/BB is a potent inducer of CCL2 gene expression. Of interest, both CCL2 and PDGF-AB/BB levels in BAL fluid were correlated positively (Fig 5, C). Of additional interest, plasmatic PDGF-AB/BB levels were also correlated with the CCL2 levels in BAL fluid (Fig 5, D). CCL2 is one of the few cytokines detected at similar levels in both plasma and BAL fluids. Plasmatic CCL2 levels were positively correlated with d-dimer levels and negatively correlated with duration of hospitalization (Fig 5, E and F).

Lastly, correlation analyses between the mediators detected in the plasma and BAL fluids of patients with severe COVID-19 and the various biologic and biochemical parameters associated with disease were performed (Fig 6). A limited number of correlations between the levels of cytokines in BAL fluids and peripheral markers were found. Levels of selected cytokines were negatively correlated with neutrophil numbers and positively correlated with AST and lactate dehydrogenase values (Fig 6, A). Regarding plasma, CCL2, CCL4, CCL5, and CCL11 were negatively correlated with duration of hospitalization and positively correlated with d-dimer levels (Fig 6, B). CCL4 and CCL5 levels were also correlated with AST and alanine transaminase levels. The levels of PDGF-AA were negatively correlated with levels of C-reactive protein and platelet-to-lymphocyte ratio.

DISCUSSION

Although patients with severe COVID-19 show an overwhelming inflammation that can ultimately affect several organs, the lung is the primary organ in which the infection develops. It therefore made sense to us to study in detail the organ first affected by the virus and from which most complications ultimately develop. To reach our goal, the cytokine, eicosanoid, and cellular contents of BAL fluids of 45 patients with severe COVID-19 (not currently being treated with steroids or antivirals) were analyzed. BAL fluids of patients with severe COVID-19 contain a large infiltrate of neutrophils and lymphocytes whose migration from blood and entry into the lung extravascular space is fueled by excessive production of chemoattractants and eicosanoids (Fig 7). The BAL fluid samples of patients with severe COVID-19 contain elevated levels of several inflammatory mediators, dominated by CC and CXC chemokines. Our results also indicate that within BAL fluids, the levels of most cytokines, chemokines, and eicosanoids were highly correlated, whereas few correlations between BAL fluid and plasma cytokine contents were observed.

Initial reports have demonstrated increased cytokine and chemokine levels in plasma or serum samples of patients with COVID-19. As such, increased plasmatic levels of IL-6, CXCL8, and TNF-α in patients with severe COVID-19 were previously reported. Our analysis of plasma from patients with severe COVID-19 confirm the reports of elevated cytokine levels published by several groups. The originality of our work lies in the comparison of cytokines and chemokines in the lungs (BAL fluid) of patients with severe COVID-19 with those in healthy controls. Our results show that levels of several cytokines, including IL-1α/β, IL-6, and TNF-α/β, were elevated in the BAL fluid of patients with severe COVID-19. However, the most abundant cytokines detected in the BAL fluid of patients with severe COVID-19 were CXC and CCL chemokines. This is in agreement with a report by Liao et al that identified CXCL8 as a predominant cytokine in the BAL fluid of patients with severe COVID-19. In a follow-up article, the same group provided evidence that monocytes and macrophages in BAL fluid of subjects with severe COVID-19 express higher levels of multiple chemokine genes than their blood counterparts do. Such transcription profiles

FIG 3. Spearman correlations between cytokines in BAL fluid and plasma of subjects with severe COVID-19. A, CC and CXC chemokines correlations. B, Cytokines correlations. Blue indicates positive correlations, and red indicates negative correlation.
translated into increased protein expression, with CXCL8 being the most abundantly detected chemokine in BAL fluid. It should also be pointed out that our measurements made from BAL fluid are likely to be underestimated relative to plasmatic concentrations considering that to obtain BAL fluid, a 100-mL bolus of saline is injected into the subsegmental bronchus, thereby diluting the bronchoalveolar fluid present in the sampled lung area. Thus, the reported concentrations of analytes in BAL fluid underestimate the actual concentrations present in the alveolar space. Our study indicates that CXCL1 is equally as abundant as CXCL8. Both of these chemokines are likely produced by alveolar macrophages or lung epithelial cells in response to...
infection. Both CXCL1 and CXCL8 are among the most potent chemoattractants for neutrophils (reviewed in Metzemaekers et al). Neutrophil influx into the extravascular compartments of the lungs is a characteristic of ARDS. The substantial influx of neutrophils detected in the BAL fluid of subjects with severe COVID-19 is therefore consistent with the presence of high concentrations of CXCL1 and CXCL8. The results of our work are in accordance with those of previous studies demonstrating an influx of neutrophils in alveolar spaces of patients with severe COVID-19. A lack of significant correlation between neutrophil numbers and clinical outcomes was also observed by Pandolfi et al. Our work is also in accordance with that of Liao et al in reporting that CC and CXC chemokines are the most abundant inflammatory mediators in BAL fluid of patients with severe COVID-19. Lastly, the results of our work agree with those of Grant et al, indicating that both neutrophils and lymphocytes represent the majority of cells present in BAL fluid from subjects with severe COVID-19. Increased CXCL8 levels play a key role in acute SARS infection, viral bronchiolitis pathogenesis, severe immunopathology, and disease enhancement during human respiratory syncytial virus infection. In patients infected with measles virus, the CXCL8 levels in BAL fluid were markedly

**FIG 5.** PDGF-AB/BB and CCL2 in BAL fluid and plasma. A, Concentrations of PDGF-AB/BB in plasma of healthy individuals and patients with severe COVID-19. B, Concentrations of PDGF-AB/BB in BAL fluid of healthy individuals and patients with severe COVID-19. C, Correlation between PDGF-AB/BB and CCL2 in BAL fluid of patients with severe COVID-19. D, Correlation between PDGF-AB/BB in plasma and CCL2 in BAL fluid of patients with severe COVID-19. E, Correlation between CCL2 and D-dimer levels in plasma of patients with severe COVID-19. F, Correlation between CCL2 and duration of hospitalization of patients with severe COVID-19. Nonparametric Spearman correlation coefficients were calculated to study the association between cytokines. ****P < .0001, as determined by using the Mann-Whitney nonparametric test.
increased and characterized by a significantly higher percentage of neutrophils than in control subjects. Increased levels of IL-1β and IL-1α have also been associated with acute inflammatory responses leading to mortality and severe pathogenesis, as well as to induction of the inflammatory loop following influenza virus infection. The lung lower respiratory tract immunopathology in Middle East respiratory syndrome CoV–infected patients was associated with high expression of the inflammatory cytokines...
and chemokines IL-1α, IL-1β, and CXCL8. In contrast, in the BAL fluid from patients with severe pneumonia caused by influenza (H1N1) virus, only IL-1β, and not IL-6/CXCL8 and TNF-α, was present at detectable levels. These results suggest that different viruses can cause severe lung pathologies by modulating the expression of a variety of inflammatory mediators. Additionally, the work of Williams et al teaches us that CCL2 and CCL7, the levels of both of which are significantly elevated in the BAL fluid of patients with ARDS as well as in that of patients with severe COVID-19, enhance chemotaxis of neutrophils to CXCL8, which is suggestive of a synergistic amplification loop existing between these 3 chemokines. Another potent neutrophil chemoattractant is LTB₄. LTB₄ belongs to a class of lipids involved in host defense and inflammation. Increased levels of LTB₄, LTB₄ metabolites, and other eicosanoids were measured in BAL fluid of subjects with COVID-19, suggesting that LTB₄ likely contributes to the observed neutrophil pulmonary influx recorded. These results are concordant with those of the study of Schwarz et al and a recently published study in which the lipidome present in BAL fluid of patients with severe COVID-19 was analyzed. Lymphocytes were also detected at high numbers in the BAL fluid of patients with severe COVID-19. Although the characterization of lymphocyte subpopulations was not performed, many of them, such as natural killer, natural killer T-, T₉₁, and regulatory T-cell subpopulations express 1 or several chemokine receptors such as CCR4, CCR5, and CXCR3, arguing that chemokines such as CCL2, CCL3, CCL4, CCL5, CXCL9, and CXCL10 (which are all elevated in the lungs of patients with COVID-19) are likely contributing to lymphocyte recruitment. CCL5 (regulated upon activation, normal T-cell expressed and secreted [RANTES]), CCL7 (monocyte chemoattractant protein-3), and CCL11 (eotaxin) levels were also significantly elevated in the BAL fluid of patients with COVID-19. The presence of such cytokines, which are potent chemoattractants for eosinophils, is consistent with the influx of such granulocytes into the extravascular compartment of the lungs. Although some statistical significance was observed between the controls and patients with COVID-19, very little IFN-α, IFN-γ, and IFN-λ2 (IL-28A) was detected in both the plasma and BAL fluid. This is in agreement with the findings of previous studies showing that SARS-CoV-2 infection was associated with a very weak, almost inexistent, interferon response. Such findings can be explained, at least in part, by studies indicating that SARS-CoV-2 encodes numerous proteins capable of inhibiting type I interferon synthesis and signaling.

Besides patients with ARDS, patients with severe COVID-19 are often affected by several extrapulmonary complications, including multiple thrombotic events indicative of platelet activation (reviewed in Gupta et al). Platelets contain α- and dense granules that store numerous CXC and CC chemokines, growth factors, bioactive amines (serotonin and histamine), and proteases. Platelets are a major source of CXC chemokines, including CXCL4 (PF4), CXCL11, CXCL12 (SDF-1), and CXCL16, and CCL chemokines such as CCL5/RANTES. Although plasma is frequently used to assess the presence of circulating cytokines, platelets are not always depleted of plasma preparation in all studies, thus leading to misleading observations. In our study, we depleted platelets by centrifugation, which
permitted evaluation of circulating inflammatory mediators released in the extracellular milieu. In a recent article, we documented that platelets were hyperactivated during COVID-19, that viral RNA can be found associated with platelets, and that increased platelet contents indicative of platelet activation and degranulation are detected in patients’ plasma. Furthermore, our work also indicates that platelets from patients with COVID-19 are hyperresponsive to thrombin relative to platelets of subjects with ARDS unrelated to COVID-19. In the current study, we have provided evidence that plasma and BAL fluid of patients with severe COVID-19 contain significantly elevated levels of CXCL1, CXCL8, CXCL12, CCL2, CCL3, CCL5, EGF, VEGF, and PDGF-AB/BB, all of which can be found in platelet granules, arguing that platelets are important contributors of the hyperinflammation observed in patients with ARDS. In fact, many of these cytokines, chemokines, and growth factors work in synergy, fueling the inflammatory response through autoimmune and paracrine pathways.

Overall, our results indicate that BAL fluid of subjects with severe COVID-19 contained very high concentrations of the following cytokines: CXCL1 > CXCL8 > CCL2 > CXCL9 > CXCL15. Cytokines such as IL-1β, TNF-α, and IL-6 were present at much lower concentrations. Several ongoing trials are currently exploring the possibility of using biologics (anti–IL-1, anti–IL-6, and anti–TNF-α) that were initially developed for the treatment of chronic inflammatory disease such as rheumatoid arthritis. Time will tell whether such specific treatments will provide clinical benefits to patients with severe COVID-19. Our results would argue that drugs with broader anti-inflammatory activities, such as the blockade of cytokine signaling (eg, Janus kinase [JAK] inhibition), would provide the greater benefits. In support of this argument, relative to remdesivir-treated patients with COVID-19, those receiving remdesivir plus baricitinib (a JAK inhibitor with activity against JAK1 and JAK2) had reduced recovery times and improved clinical status, notably among those receiving high-flow oxygen or noninvasive ventilation. Recent data from the RECOVERY trial also indicate that administration of dexamethasone, a glucocorticoid that inhibits neutrophil migration (among other effects), resulted in a reduced 28-day mortality of patients with COVID-19. With regard to platelets, there are currently insufficient data to recommend either for or against using therapeutic doses of antithrombotic or thrombolytic agents for COVID-19 in patients who are hospitalized.

Our study has the following limitations. First, our patients with severe COVID-19 were older than our healthy controls (both for obtaining plasma and for obtaining BAL fluid), which could have had an impact on the level of certain mediators measured. Second, the procedure to obtain BAL fluid was slightly different between healthy subjects and patients with severe COVID-19. The volume of saline injected into healthy subjects was 50 mL, whereas that injected into patients with severe COVID-19 was 100 mL. The possible outcome of this discrepancy could be an underestimation of lipid levels in 1 group versus the other. Third, the leukocyte counts in the BAL fluid of patients with severe COVID-19 did not include the number of alveolar macrophages or a detailed characterization of the various lymphocyte populations. Such data would have helped us define more precisely the inflammatory signature in the lungs of patients with severe COVID-19. Fourth, our patients with COVID-19 were mostly of Arabic origin whereas the controls for BAL fluid were White. Whether ethnicity affected the outcome of our analysis is undetermined. Lastly, for the control group, plasma and BAL fluid were not obtained from the same individuals. Considering that the levels of most analytes in plasma and BAL fluid of control subjects are typically near or below the detection limits of the assays, we do not consider this difference to have affected our results.

In conclusion, our work provides evidence that the content of inflammatory mediators in the lungs differs from that detected in the blood. CXC and CC chemokines are by far the most prevalent inflammatory mediators, and their presence is associated with massive influx of neutrophils and lymphocytes into the extravascular compartments of the lungs. To be successful, the development of effective anti-inflammatory strategies to help reduce COVID-19 morbidities should take such information into consideration.

The graphical abstract and Fig 7 were created with Biorender.com.

REFERENCES

1. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020;579:269-72.
2. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020;71:762-8.
3. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180:934-43.
4. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271-80.e8.
5. Chen N, Zhou M, Dong X, Qi J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-13.
6. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
7. Calfee CS, Delucchi KL, Sinha P, Matthey MA, Hackett J, Shankar-Hari M, et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med 2018;6:691-8.
8. Famous KR, Delucchi K, Ware LB, Kangarliris KN, Liu KD, Thompson BT, et al. Acute Respiratory distress syndrome subphenotypes respond differently to randomised fluid management strategy. Am J Respir Crit Care Med 2017;195:331-8.
9. Sinha P, Delucchi KL, Thompson BT, McAleer DF, Matthey MA, Calfee CS, et al. Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study. Intensive Care Med 2018;44:1859-69.
10. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:420-2.
11. Luo M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med 2020;26:842-4.
12. Leng L, Cao R, Ma J, Mou D, Zhi Y, Li W, et al. Pathological features of COVID-19-associated lung injury: a preliminary proteomics report based on clinical samples. Signal Transduct Target Ther 2020;5:240.
13. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nörenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 2020;26:1636-43.
14. Han H, Yang L, Liu R, Liu F, Wu KL, Li J, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med 2020;58:1116-20.
15. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18:844-7.
16. Zaid Y, Puhm F, Allaey S, Nagy A, Oudhiri M, Khaliki L, et al. Platelets can associate with SARS-CoV-2 RNA and be hyperactivated in COVID-19. Circ Res 2020; 127:1404-18.
17. Zhang H, Zhou P, Wei Y, Yue H, Wang Y, Hu M, et al. Histopathologic changes and SARS-CoV-2 immunostaining in the lung of a patient with COVID-19. Am Intern Med 2020;172:629-32.
18. Xu G, Qi F, Li H, Yang Q, Wang H, Wang X, et al. The differential immune response to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing. Cell Discov 2020;6:73.
19. Schwarz B, Sharma L, Roberts L, Peng X, Bermejo S, Leighton I, et al. Cutting edge: severe SARS-CoV-2 infection in humans is defined by a shift in the serum lipidome, resulting in dysregulation of eicosanoid immune mediators. J Immunol 2021;206:329-34.
20. Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA 2012;307:2526-33.
21. Turcotte C, Archambault AS, Dumas E, Martin C, Blanchet MR, Bissotnette E, et al. Endocannabinoid hydrolysis inhibition unmasks that unsaturated fatty acids induce a robust biosynthesis of 2-arachidonoyl-glycerol and its congeners in human myeloid leukocytes. FASEB J 2020;34:4253-65.
22. Chu Y, Ge Y, Wu B, Zhang W, Wu T, Wen T, et al. Serum cytokine and chemokine profile in relation to the severity of coronavirus disease 2019 in China. J Infect Dis 2020;222:746-54.
23. Becker S, Quay J, Koren HS, Haskell JS. Constitutive and stimulated MCP-1, G alpha, beta, and gamma expression in human airway epithelium and bronchoalveolar macrophages. Am J Physiol 1994;266:H1:141-287-86.
24. Garofalo R, Sabry M, Jamaluddin M, Yu RK, Casola A, Ogra PL, et al. Transcriptional activation of the interleukin-8 gene by respiratory syncytial virus infection in alveolar epithelial cells: nuclear translocation of the RELA transcription factor as a mechanism producing airway mucosal inflammation. J Virol 1996;70:8773-81.
25. Metzemaekers M, Goure F, Proost P. Neutrophil chemotactic receptors in health and disease: double-edged swords. Cell Mol Immunol 2020;17:433-50.
26. Steinberg KM, Milberg JA, Martin TR, Maunder RJ, Cockrell BA, Hudson LD. Evolution of bronchoalveolar cell populations in the adult respiratory distress syndrome. Am J Respir Crit Care Med 1994;150:113-22.
27. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford AM, et al. Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome. BMC Pulm Med 2020;20:301.
28. Grant RA, Morales-Nebreda L, Markos NS, Swaminathan S, Querrey M, Guzman JM, et al. Impaired levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients. FASEB J 2021;35:e21666.
29. Hadjadj J, Yatin N, Barnabei L, Corneau A, Bourrier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 2020;369:718-24.
30. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Moller R, et al. Impaired host response to SARS-CoV-2 drives development of COVID-19. Cell 2020;181:1036-45.e9.
31. Lei X, Dong X, Ma R, Wang W, Xiao X, Tian Z, et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun 2020;11:3810.
32. Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, Smith MJ, Leukotriene B4, et al. A potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980;286:264-5.
33. Williams AE, Joe RJ, Mercer PF, Brealey D, Fareh D, Thrack D, et al. Evidence for chemokine synergy during neutrophil migration in ARDS. Thorax 2017;72:66-73.
34. Foxworth-Jones AW, Bray MA, Doig MV, Shipley ME, Smith MJ. Leukotriene B4, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980;286:264-5.
35. Estella A. Cytokine levels in bronchoalveolar lavage and serum in 3 patients with 2009 influenza A/H1N1v severe pneumonia. J Infect Dev Cities 2011:5:540-3.
36. Min CK, Cheon S, Ha NY, Sohn KM, Kim Y, Aigerim A, et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci Rep 2016;6:25359.
37. Zhou J, Chu H, Li C, Wong BH, Cheng ZS, Poon VK, et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J Infect Dis 2014;209:1331-42.
38. Estella A. Cytokine levels in bronchoalveolar lavage and serum in 3 patients with 2009 influenza A/H1N1v severe pneumonia. J Infect Dev Cities 2011:5:540-3.
FIG E1. Spearman correlation between cytokines and chemokines in plasma and in BAL fluids of subjects with severe COVID-19.
| Index                                      | Total (n = 45) |
|--------------------------------------------|----------------|
| N/A                                        | 4              |
| Nothing to report                          | 24             |
| Coronary heart disease + type 2 diabetes   | 2              |
| Arterial hypertension + heart failure      | 1              |
| Asthma                                     | 1              |
| Type 2 diabetes                            | 2              |
| Carcinoma                                  | 3              |
| Chronic inflammatory rheumatism            | 1              |
| Arterial hypertension + coronary heart disease | 1          |
| Chronic inflammatory arthritis             | 1              |
| Benign prostatic hyperplasia               | 1              |
| Obesity                                    | 1              |
| Alzheimer disease                          | 1              |
| Rheumatoid arthritis                       | 1              |
| Urinary system disease                     | 1              |

NA. Not available.
### TABLE E2. Medication (not related to COVID-19 treatment)

| Index                                                                 | Total (n = 45) |
|----------------------------------------------------------------------|----------------|
| N/A                                                                  | 5              |
| Nothing to report                                                    | 26             |
| Chemotherapy + statins                                               | 1              |
| Chemotherapy (Everolimus)                                            | 2              |
| Methotrexate + corticotherapy                                        | 1              |
| Femara                                                               | 1              |
| Metformin                                                            | 2              |
| Metformin + Gliclazide                                               | 1              |
| Acetyl salicylic acid + Bisoprolol + Metformin + Irbesartan/Amlodipine + Lorazepam | 1              |
| Methotrexate + corticotherapy                                        | 2              |
| Propranolol                                                          | 1              |
| Clopidogrel                                                          | 1              |
| Salbutamol                                                           | 1              |

*NA*, Not available.